top of page

GSK and Lyell Immunopharma join in developing cell therapies against solid tumours

GlaxoSmithKline announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company. The partnership is intended to develop cell therapies for solid tumors.

The partnership helps to strengthen GSK3377794, which targets NY-ESO-1 antigen, which is commonly expressed in several cancers.

GSK made a statement that the two cell therapies approved are for blood-borne cancers with no engineered T cells available for common solid tumors. GSK expects to maximize its activity with the collaboration to develop T cell therapies for treating solid tumors, which have high unmet need.

The company expected that by “improving the fitness” of T cells and delaying T cell exhaustion, engineered T cells could act against solid tumors.

Dr. Hal Barron, Chief Scientific Officer, and President, R&D, GSK, said “We are witnessing significant scientific innovation in cell and gene therapies, transforming the treatment of some blood-borne cancers, but patients with solid tumors are in need of equally effective treatments. Applying Lyell’s novel approach to counter T cell exhaustion and working with world-class scientists, such as Rick Klausner and his impressive team, increases our probability of delivering the next generation of cancer cell therapies for patients with solid tumors.”


Recent Posts

See All
bottom of page